RxDoctor Payments Data

Frank Scott, MD

Nephrology · Gadsden, ALNPI 1508804733

Payments from drug & device makers

$4,018in general payments, 2019–2025

Across 19 payments — averaging $211.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Outset Medical Inc$3K
  • Ceribell, Inc.$278
  • Astellas Pharma US Inc$235
  • Merck$125
  • Teva Pharmaceuticals USA, Inc.$122
  • Takeda Pharmaceuticals U.S.A., Inc.$115
  • plus $343 from 6 others

What the payments were for

  • Consulting fees$1,40035%
  • Speaking & faculty fees$1,40035%
  • Food & beverage$1,21830%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,018 in reported general payments places this provider in the 60th percentile of 164 nephrology providers in Alabama.

See all nephrology providers in Alabama

Medicare billing

Part B allowed, 2024
$182,820
Medicare patients
491
Services billed
1,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$33,015
XifaxanRifaximin14$22,777
VraylarCariprazine Hcl15$10,830
MyrbetriqMirabegron33$7,636
FarxigaDapagliflozin Propanediol17$5,364
JanuviaSitagliptin Phosphate17$5,053
Daptomycin12$4,861
ErtapenemErtapenem Sodium13$3,577
Risperidone OdtRisperidone15$2,322
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$2,110
CeftriaxoneCeftriaxone Sodium27$1,887
Atorvastatin Calcium57$1,293
Duloxetine Hcl56$1,173
Cefdinir77$1,168
Levothyroxine Sodium79$1,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$235$7,63633 claims
AstraZenecaFarxiga$59$5,36417 claims
MerckJanuvia$125$5,05317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 164 nephrology providers in Alabama.

Other nephrology in Gadsden

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →